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RECIST revised: implications
for the radiologist. A review article
on the modified RECIST guideline
Abstract The purpose of this review
article is to familiarize radiologists
with the recently revised Response
Evaluation Criteria in Solid Tumours
(RECIST), used in many anticancer
drug trials to assess response and
progression rate. The most important
modifications are: a reduction in the
maximum number of target lesions
from ten to five, with a maximum of
two per organ, with a longest diameter
of at least 10 mm; in lymph nodes
(LNs) the short axis rather than the
long axis should be measured, with
normal LN measuring <10 mm, non-
target LN ≥10 mm but <15 mm and
target LN ≥15 mm; osteolytic lesions
with a soft tissue component and
cystic tumours may serve as target
lesions; an additional requirement for
progressive disease (PD) of target
lesions is not only a ≥20% increase in
the sum of the longest diameter (SLD)
from the nadir but also a ≥5 mm
absolute increase in the SLD (the other
response categories of target lesion are
unchanged); PD of non-target lesions
can only be applied if the increase in
non-target lesions is representative of
change in overall tumour burden;
detailed imaging guidelines. Alterna-
tive response criteria in patients with
hepatocellular carcinoma and gastro-
intestinal stromal tumours are dis-
cussed.
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Introduction
Although improvement of clinical symptoms and survival
are considered the ultimate proof of the effectiveness of
anticancer drugs, surrogate endpoints based on radiological
measurements are increasingly used to assess therapeutic
effects. Such radiological measurements give early and
objectively based information.
In 1979, theWorld Health Organisation (WHO) published
objective tumour response criteria, which were adopted
around the world [1, 2]. Due to differences in the interpre-
tation and application of these criteria, a task force proposed
a simplified set of standardised criteria in 2000: Response
Evaluation Criteria in Solid Tumours (RECIST) [3]. Both
WHO criteria and RECIST depend heavily on change in
tumour size depicted on imaging studies. RECIST have
largely replaced the WHO guidelines. Nevertheless, since
their introduction RECIST have also received criticism. The
RECISTWorking Group acknowledged that RECISTwould
not solve all issues regarding the adequate monitoring of
tumour response. Recently, they have published their revised
RECIST guideline (version 1.1) to simplify, optimise and
standardise the original criteria [4].
This review article discusses RECIST and their mod-
ifications, and reviews the issues of concern and debate.
The focus will be on issues that are of interest and relevant
to radiologists.
RECIST 1.0
RECIST 1.0 divides lesions into measurable and non-
measurable lesions before the start of therapy [3]. There
should be at least one measurable lesion in a patient.
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Measurable lesions are lesions that can be accurately
measured and have a longest diameter of ≥10 mm on
computed tomography (CT) or magnetic resonance imag-
ing (MRI) and ≥20 mm on conventional radiographs at
baseline. In RECIST 1.0, up to ten lesions should be
measured, up to five per organ (target lesions). The sum of
the longest diameter of the target lesions (SLD) is
calculated. At each time point, the same target lesions are
to be measured.
Baseline SLD, measured ≤4 weeks before start of
treatment, is the reference for assessment of tumour
response. The ‘nadir’, the smallest SLD during treatment,
is the reference for assessment of tumour progression.
It is important that the radiologist, who is responsible for
the selection of target lesions, chooses the most appro-
priate, preferably the largest, target lesions that reflect the
overall tumour load, possibly including all involved organs
and those that can be accurately measured and followed.
All other lesions are regarded as non-target lesions.
These include: the remainder of the measurable lesions,
lesions smaller than required for target lesions, cystic and
bone lesions and truly non-measurable lesions, such as
effusions, leptomeningeal disease and lymphangitis. The
non-target lesions do not need to be measured, but the
presence and extent need to be specified in the radiological
report at each time point.
CT is the preferred imaging technique, but MRI and
chest radiography are also allowed. The same imaging
method should be applied throughout the study.
Four response categories for target lesions are defined as:
complete response [(CR) complete disappearance of all
lesions, confirmed at ≥4 weeks], partial response [(PR) a
≥30% decrease in SLD from baseline, confirmed at ≥4weeks],
progressive disease [(PD) a ≥20% increase in SLD from
smallest SLD] and stable disease [(SD) neither PR nor PD].
The overall response in RECIST 1.0 is based on the
response of target lesions, non-target lesions and the
appearance of new lesions. The response of non-target
lesions can only confirm or aggravate the outcome of the
target lesions.
RECIST 1.0 contains an appendix with some specifica-
tions for radiologic imaging to ensure standardised
protocols.
RECIST 1.1
Initially, RECIST 1.0 criteria were widely adopted, but
since their publication several questions and issues have
arisen. The most important questions regard the potential
role of modern imaging modalities, which may (also) give
a functional rather than anatomical response assessment,
the replacement of unidimensional by volumetric tumour
measurements, application of RECIST in non-cytotoxic
drugs, the optimal number of lesions to be measured and
assessment of lymph nodes.
Another drawback is that RECIST is not applied in
malignant lymphoma patients, for whom alternative inter-
national guidelines exist [5].
The RECIST Working Group has gathered and inves-
tigated a vast database, consisting of more than 6,500
patients with over 18,000 target lesions, included in 16
large trials from 1993 till 2005. From analysis of this
database, together with a review of the literature, it has
addressed the points of debate in the updated RECIST
(version 1.1) in January 2009 [4].
The major changes between RECIST versions 1.0 and
1.1 that are important for radiologists are summarised in
Table 1. All issues are discussed below.
Number of lesions to be measured
Since the ten lesions to be measured according to RECIST
1.0 was an arbitrarily selected number, the RECIST
Working Group retrospectively calculated from their
database the effect of assessing one, two, three or five
target lesions instead of ten on the response and progres-
sion outcome [6]. Assessment of three or five lesions did
not change the overall response rate or progression-free
survival.
A statistical simulation model also showed little
difference between response assessments based on five
target lesions compared with ten, but a smaller number of
lesions tended to overestimate the response rate [7].
In a computer analysis simulating all possible combina-
tions of lesions from unidimensional lesion measurements,
the variance in response assessment was decreased by 90% if
at least four lesions were measured instead of only one [8].
Therefore, in RECIST 1.1 the maximum number of
target lesions is five, with a maximum of two per organ [4].
Some phase III trials allow inclusion of patients without
measurable lesions, if only progression-free survival or
time to progression are primary endpoints, not objective
tumour response. Additional notes on assessment of PD in
these patients and an additional table on overall response
are included in the revised guideline [4], but this is not
further discussed in this article.
Measurements of targets lesions
The longest diameter should always be measured, in
principle, in the axial plane, even if the level or the
orientation of the longest diameter of the lesion has
changed on follow-up examinations [4].
The margin of target lesions should be carefully
identified and measurements should include the whole
lesion (Fig. 1).
If a lesion on follow-up breaks into separate fragments,
the sum of the fragments should be added and similarly, if
lesions coalesce, the longest diameter of the merged lesion
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should be measured [4]. In isotropic CT or MRI, lesions
may be measured in the coronal or sagittal plane if this is
more appropriate [4].
On CT, it is recommended for purposes of consistency
and radiation protection to reconstruct 5-mm slices (or less)
contiguously. To avoid partial volume averaging effects
and, therefore, inconsistent measurements of the same
lesion between serial CT examinations, a measurable lesion
should be at least twice the slice thickness at baseline, i.e.
10 mm if slice thickness is 5 mm. This is also applicable for
MRI examinations. For chest X-rays, the minimum target
lesion size remains 20 mm, provided that the lesion is
surrounded by pulmonary parenchyma [4]. Watanabe et al.
[9] confirmed that a minimum lesion size increased the
reproducibility of unidimensional measurements in non-
small cell lung cancer patients.
If at follow-up, a target lesion is still visible, but ‘too
small to measure’, it should be assigned a default
measurement of 5 mm to avoid false classification of
response or PD, secondary to inaccurate measurements [4].
Since potentially false classification of PD may be due to
inaccurate measurements in small residual lesions, PD in
Fig. 1a, b CT image in the portal-venous phase of a 34-year-old
man with liver metastasis of a adrenocortical carcinoma. The
hyperdense rim of this liver metastasis (arrows) is only faintly
visible on soft tissue settings (a), but better appreciated when
window width and window level are adjusted to the liver (b). Not
only the necrotic centre but also the rim should be included in
measuring this lesion
Table 1 Summary of the major changes between RECIST 1.0 and 1.1, relevant to radiologists (modified from Appendix I [4]) (LN lymph
node, CR complete response, SLD sum of longest diameter, PD progressive disease, PET positron emission tomography)
Criteria RECIST 1.0 RECIST 1.1
Assessment of overall tumour
burden
Measuring maximum of ten lesions
(5 per organ)
Measuring maximum of five lesions (two per organ)
Minimum size of measurable
lesions
CT: 10 mm (spiral) or 20 mm (non-spiral) CT: 10 mm (when slice thickness is ≤5 mm); or
2× slice thickness (when slice thickness is >5 mm)
Specifications on LNs Not mentioned CT: ≥15 mm short axis for target, ≥10-<15 mm for
non-target, <10 mm is non-pathological
Specifications on measurability No specifications Special notes on bone lesions and cysts
CR of target lymph nodes Not specified LN <10 mm short axis is CR (also implying SLD
may ≠ 0 in CR)
PD of target lesions PD: ≥20% increase over smallest
SLD
PD: ≥20% increase over smallest SLD AND ≥5 mm
increase of target lesions together
PD of non-target lesions Increase in size of one or a few non-target
lesions is considered PD, even when
target lesions are stable or responding
Specification: increase of non-target lesions is only
PD, if the increase is representative of change in
overall tumour burden
New lesion Not specified Detailed description when lesion is considered new
Overall response No special notes Notes on residual tissue, including LNs
Imaging appendix Appendix I: contains some specifications
for imaging
Appendix II: updated with detailed guidance on use of
MRI, FDG-PET(/CT) and other practical issues
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RECIST 1.1 requires not only an increase of SLD of target
lesions of ≥20% over the smallest SLD during the study
(unchanged from RECIST 1.0) but also that the target
lesions together increase ≥5 mm [4].
An exception to measuring the longest diameter is in
patients with malignant pleural mesothelioma. It was
reported that the non-spherical growth pattern in this
disease makes reproducible RECIST measurements diffi-
cult [10]. Byrne et al. [11] proposed modified RECIST
criteria, in which tumour thickness perpendicular to the
chest wall rather than the longest diameter is measured in
fixed positions related to anatomical landmarks (Fig. 2).
They found good correlation with outcome; this was
confirmed [12].
Unidimensional and volumetric measurements
The issue whether unidimensional measurements represent
adequate assessment of total tumour burden has often been
questioned. The RECIST Working Group stated from a
retrospective analysis of more than 4,600 patients in 14
trials [3], based on the model proposed by James et al. [13]
that application of unidimensional rather than the bidimen-
sional measurements used in the WHO criteria, showed no
difference in response and progression rate. This was
confirmed by others [14–16], but a retrospective statistical
simulation to change tumour shape, showed a decrease in
concordance between uni- and bidimensional measure-
ments when lesions became more irregular [17]. Schwartz
et al. [18] also found a greater discordance between uni-
and bidimensional measurements in more ellipsoid lesions
compared with spherical lesions.
Another concern is the inter- and intra-observer variability
of manual measurements. In general, inter-observer variabil-
ity is greater than intra-observer variability [19], especially in
irregular and poorly defined lesions [20]. This may lead to
substantial differences in response assessment [21].
With the available 3D software tools on modern CT and
MRI equipment, the reproducibility of semi-automated
volumetric measurements of metastases has been exten-
sively investigated. Wormanns et al. [22] showed good
repeatability of semi-automated volumetric measurements
of small lung nodules, but an irregular shape degrades the
segmentation process, contributing to larger variability
[23]. Marten [24] reported significantly better inter- and
intra-observer variability and treatment response assess-
ment for semi-automated than for manual volumetric
measurements in small pulmonary metastases. Volumetric
measurements have also proved reliable in low contrast-to-
noise areas, such as the liver [25], lymph nodes [26] and
brain [27]. Nevertheless, although these results are
promising, they have all been performed in single
institutions with a variety of different software tools that
are not widely available. There are no robust data yet to
justify replacement of unidimensional measurements with
volumetric assessment at this moment [28].
Ultrasound
Ultrasound is operator dependent; measurements on ultra-
sound are subjective and they cannot be reproduced for
independent review. Therefore, it should only be used as an
adjunct to clinical measurements, e.g. to measure superfi-
cial lymph nodes and subcutaneous lesions [4]. There has
been concern from paediatric radiologists about radiation
exposure because of the repeated use of CT in paediatric
patients, whose prognosis may be fair to good [29]. The
RECISTWorking Group acknowledges the widespread use
of ultrasound in daily paediatric oncology practice, but in
the case of a phase II trial of a potential new anticancer
drug, reproducibility of measurements is mandatory,
thereby disqualifying ultrasound [4, 30].
Assessment of lymph nodes
RECIST 1.0 [3] does not specifically address the issue of
lymph nodes. This implies that the longest axial diameter of
lymph nodes should be measured according to RECIST 1.0.
Since lymph nodes are anatomical structures that are
normally shown by CT in various locations, a metastatic
deposit in a lymph node that disappears completelywill often
still be visible as a normal sized lymph node on follow-up,
thereby precluding CR, as was pointed out by the Interna-
tional Cancer Imaging Society [31]. Furthermore, it is well
recognised that the short axis of lymph nodes is more
reproducible than the long axis [32] and is a better predictor
Fig. 2 On this CT image of the chest of a 30-year-old female patient
with mesothelioma, the longest diameter of the tumour is
represented by the arrow, but the measurement perpendicular to
the chest wall (dotted line) better represents tumour volume and is
therefore more reliable
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than the long axis for the presence of metastatic disease [33]
and the response to chemotherapy [18].
In RECIST 1.1 [4], these issues are addressed. A lymph
node is considered metastatic if at baseline the short axis is
≥10 mm. It is measurable (may serve as target lesion) if the
short axis is≥15mm.A lymph nodewith a short axis≥10mm,
but <15mmat baseline is considered a non-target lymph node.
If the short axis of a lymph node on follow-up studies drops
below 10 mm, it is no longer considered pathologic, although
continued measurement is needed to assess progression of
these nodes on follow-up. This implies that a CR in patients is
possible, while their SLD is not zero, if one or more target
lesions are lymph nodes and all these lymph nodes have a
short axis <10 mm on follow-up (Fig. 3) [4].
The RECIST Working Group has applied these new
criteria on patients in their database [34]. As was expected,
there was a higher percentage of patients with CR in
RECIST 1.1 whom were considered PR in RECIST 1.0.
They also found a 3.0% increase in the overall response
compared with RECIST 1.0, if only lymph nodes were
investigated. This is explained by a greater size reduction
of the small axis of lymph nodes (measured in RECIST
1.1), compared with the size reduction of the long axis
(measured in RECIST 1.0).
Although the normal size of lymph nodes varies
considerably depending on their location [32, 35] and a
short axis over 10 mm is not specific for metastatic disease
[36], the RECIST Working Group considers a short axis of
10 mm an acceptable cut-off point between pathological
and normal and has chosen this measurement for reasons of
simplicity [4].
Specifications on bone lesions and cysts
In general, bone lesions are not considered ‘measurable’,
since often only change in appearance and not in size is
noted on follow-up CT (Fig. 4). According to RECIST 1.1,
only lytic or mixed lytic-blastic bone lesions with an
identifiable soft tissue component may be used as target
lesions, provided that the soft tissue component meets the
criteria for measurability [4].
Skeletal scintigram, fluorodeoxyglucose positron emis-
sion tomography (FDG-PET) or conventional radiographs
may only confirm the presence or disappearance of osseous
lesions. It has been shown that MRI can be used to monitor
bone metastases in prostate cancer patients during chemo-
therapy [37], but this has not yet been validated in large trials.
In RECIST 1.0, all cystic lesions are regarded as non-
measurable [3]. In RECIST 1.1, cystic and necrotic
metastases can be considered as measurable lesions,
although non-cystic lesions are preferred if present [4].
Unequivocal progression of non-target lesions
The increase in size of non-target lesions in patients is
addressed in detail in RECIST 1.1. Only if the non-target
lesions increase such that the overall tumour burden
increases substantially can a patient with PR or SD based
on target lesion response be categorised PD for non-target
lesions and, therefore, PD as overall response (see also
Table 2). Quantification of (truly non-measurable) non-target
lesions is by definition impossible, but total increase in
‘volume’ of non-target lesions should be similar to increase
in size of target lesions, e.g. at least 73% (equivalent to
increase in SLD of 20%) to categorise them as PD. Amodest
increase of one or a few non-target lesions is usually not
sufficient to qualify non-target lesion response as PD and
should not lead to discontinuation of treatment (Fig. 5) [4].
New lesions
Any new malignant lesion on follow-up implies PD. The
finding of a new lesion should, therefore, be unequivocal,
truly representing a new metastatic deposit and not
attributable to other causes.
Fig. 3 This 67-year-old male patient with non-Hodgkin lymphoma
had enlarged target (arrows) and non-target (arrowheads) retroperi-
toneal lymph nodes on this CT image at baseline (a). After
chemotherapy (b), these lymph nodes are still visible, but of normal
size, categorising this patient as CR according to RECIST 1.1
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Equivocal new lesions may be due to a change in the type
of examination (e.g. MR after CT) or technique (e.g. 3-T
rather than 1-T MRI). An equivocal new small lesion should
be followed to confirm if it truly represents a new lesion [4].
In RECIST 1.1, FDG-PET may complement CT to assess
PD in case of a possible new lesion. A negative FDG-PETat
baseline with a positive FDG-PET at follow-up is a sign of
PD based on a new lesion. A positive FDG-PET lesion
means one which is FDG-avid with an uptake greater than
twice that of surrounding tissue on the attenuation corrected
image. If no FDG-PET is performed at baseline, the
interpretation depends on the CT findings [4].
‘New’ sclerotic bone lesions may represent healing lytic
lesions that were not detected on previous examinations
(Fig. 4).
A ‘new’ lesion may also be detected in an area of the
body that was not examined at baseline, e.g. a brain
metastasis. In such cases, this lesion is considered a truly
new lesion according to RECIST 1.1, converting the
response category to PD [4]. It is important, therefore, to
image at baseline all predilection sites for metastases in the
cancer type studied and also areas based on signs and
symptoms of the individual patient.
Overall response
Table 2 contains the overall response for target and non-
target lesions in RECIST 1.1, including the response in case
of new lesions [4]. Compared with RECIST 1.0, this table is
Fig. 4a–d CT images of the
spine in a 50-year-old female
patient with bone metastases of
breast carcinoma. a At baseline,
there is an osteolytic lesion in a
thoracic vertebral body (arrow),
and no visible metastases in one
of the lumbar vertebra (b). After
chemotherapy, the thoracic os-
seous lesion has not changed in
size, but has become completely
osteoblastic (arrow in c), repre-
senting a good response. The
‘new’ sclerotic lesions in the
lumbar vertebra (arrowheads in
d), are considered responding
small osteolytic metastases that
the baseline CT failed to identi-
fy. This patient also had a PR in
soft tissue lesions (not shown)
Table 2 Overall response in RECIST 1.1 [4] (CR complete








CR CR No CR
CR Non-CR/non-PD No PR
CR Not all evaluated No PR
PR Non-PD/not all evaluated No PR
SD Non-PD/not all evaluated No SD
Not all evaluated Non-PD No NE
PD Any Yes/no PD
Any PD Yes/no PD
Any Any Yes PD
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updated with the response category ‘NE’: non-evaluable.
This is to be assigned at a time point during follow-up if not
all target lesions are evaluated at that time point.
In case of residual disease, it may be difficult to
distinguish this from normal or benign tissue, especially in
some tumour types, e.g. non-seminomatous germ cell
tumours. In these cases, tissue confirmation (fine needle
aspiration or biopsy) or FDG-PET may be used to upgrade
the response status to CR [4].
Additional imaging specifications
Appendix II of RECIST 1.1 contains many details on the
different imaging modalities and how to perform them [4].
Many issues have already been addressed or discussed
above. Other relevant specifications are [4]:
– Intravenous contrast media administration in CT is
mandatory. Although no specific instructions are given
on the type, dose and rate of intravenous contrast
media and the timing of CT data acquisition, it is stated
that typically, CT acquisition should be performed
during the portal venous phase and that a single phase
is usually sufficient. However, triphasic CT protocols
are recommended for hepatocellular and neuroendo-
crine tumours (Fig. 6). A method of contrast media
administration should be chosen to demonstrate me-
tastases to best effect and the method should be used
consistently on follow-up CT studies. In case of contra-
indications to intravenous contrast media, the decision
on whether to perform non-contrast enhanced CT or
MRI should depend on the tumour type, the anatomic
location of the disease and the findings on prior
studies, to allow for optimal comparison and reprodu-
cibility of results. Non-contrast chest CT is preferred
over MRI or chest X-ray.
– Administration of oral contrast media is recommended
for abdominal CT.
– If FDG-PET is used in trials, it should include whole-
body images 60 min after injection with attenuation
correction. Most importantly, the method should be
consistent throughout the trial.
– PET/CT may be used if the CT is of similar diagnostic
quality as a CT performed without PET: with oral and
intravenous contrast media.
Fig. 5 This 50-year-old woman with a uterus sarcoma has several
target pulmonary metastases (arrowheads) on these CT images of
the chest at baseline (a, b). After chemotherapy (c, d), the target
lesions have disappeared or decreased in size considerably,
classifying the target lesions as PR. Only one non-target lesion
(arrow in b, d) has increased in size, but this is insufficient for
‘unequivocal progression of non-target lesions’. The non-target
lesions should be categorised as non-PD and the overall response is
therefore PR
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– MRI acquisition parameters should be specified,
optimised and consistent throughout the trial. Axial
T1- and T2- weighted and gadolinium-chelate en-
hanced sequences are recommended, preferably with
breath-holding technique and on the same (type of)
MR system, but no specifications are given. Measure-
ments should be performed on the same sequence on
serial studies.
Other issues of debate
New types of anticancer agents and local treatment
New molecular targeted agents often induce growth
inhibition rather than tumour regression [38, 39], resulting
in limited objective response rates according to RECIST,
but improved survival in a number of cancer types [40–42].
Therefore, Llovet et al. [43] have proposed amendments
to RECIST in patients with hepatocellular carcinomas
(HCCs): to assess response of target lesions, only viable
tumour should be measured, i.e. tumoral enhancement in
the arterial phase. The cut-off percentages for overall
response are similar to those in RECIST. New hepatic
nodules are considered HCCs, if they are ≥10 mm and
show hypervascularisation in the arterial phase and wash-
out in the portal-venous or delayed phase or if they show
interval growth of ≥10 mm. For lesions not typical HCCs,
conventional RECIST criteria are applied.
Choi et al. [44] showed that in patients with gastrointes-
tinal stromal tumours (GISTs) treatedwith imatinib-mesylate
(Glivec) decrease in tumour volume is also not the optimal
indicator to assess antitumour activity. Their modified
response criteria for GIST patients (a decrease in GIST size
of ≥10% or a decrease in tumour density on CT of ≥15%)
correlated better with time to progression than response
according to RECIST (Fig. 7); this was validated [45].
This indicates that these new cytostatic drugs may
require functional and molecular imaging to assess, for
example, metabolism, perfusion or diffusion characteris-
tics, rather than anatomical assessment of tumour size.
RECIST cannot be applied to evaluate local treatment of
lesions by radiofrequency ablation or cryoablation. In
successful ablation, the ablated area is larger than the
Fig. 6 In this 40-year-old man with hepatocellular carcinoma, a CT
image of the liver in the late arterial phase shows a hypervascular
tumour in the hepatic dome (arrows in a) that is well delineated
from the surrounding parenchyma, whereas the same lesion is barely
discernible from the liver parenchyma in the portal-venous phase
(arrows in b) due to early washout of contrast media
Fig. 7 CT images in the portal-venous phase of liver metastases of a
GIST in a 44-year-old man at baseline (arrows in a). The metastases
decrease somewhat in size after Glivec (arrows in b), but the most
striking difference is a decrease in density, giving the metastases a
cystic appearance. This is considered a good response according to
the Choi criteria
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original tumour and totally includes it, with no or subtle rim
enhancement. Often this area gradually decreases in size over
time and the rim enhancement disappears. Nodular enhance-
ment suggests residual or recurrent tumour [46, 47].
Alternative imaging modalities
FDG-PET or PET/CT In recent decades, FDG-PET and
PET/CT have been shown in many, often single-centre,
trials to provide earlier and more accurate response
assessment than CT: it may allow for treatment monitoring
after the first or second cycle of chemotherapy (sometimes
even within hours after administration of anticancer drugs)
and it can differentiate viable tumour from necrosis.
However, varying approaches for acquisition and image
analysis and the absence of generally accepted criteria
make comparison of study results difficult [48]. In
Hodgkin’s disease and high-grade non-Hodgkin lympho-
ma, FDG-PET results have been shown to be very accurate
and correlate with survival [49]. FDG-PET has already
been incorporated into international response criteria on
lymphoma [5]. In non-small cell lung cancer, colorectal
and breast cancer, the strength of FDG-PET may lie in
early identification of non-responders to chemotherapy
rather than assessing (complete) response [50–52]. The
main challenge is to implement and maintain standards in
larger multi-centre trials [53]. As a starting point for
further validation of FDG-PET in multi-centre studies and
meta-analyses, Wahl et al. [54] have proposed guidelines
for the standardisation of response criteria for FDG-PET,
the so-called PET Response Criteria in Solid Tumours
(PERCIST).
New developments in MRI Dynamic contrast-enhanced
MRI (DCE-MRI) has been investigated to quantify the
effect of drugs on tumour angiogenesis and vascular
disruption. Although early results show that this is indeed
feasible [55, 56], there are at present a variety of
biomarkers that can be measured in DCE-MRI. A review
of the literature has pointed out that acquisition and
analysis are very complex and concludes that further
research and validation to correlate these results to clinical
outcome measures are needed before DCE-MRI can serve
as a new surrogate endpoint [57].
Experience in diffusion-weighted MRI in monitoring
treatment response has so far been limited [58]. Recom-
mendations on standardisation of the application have
recently been published [59].
Perfusion CT Perfusion CT is also very promising in
monitoring treatment response to anti-angiogenic drugs
[60, 61], but at this moment a variety of mathematical
methods (including compartmental and deconvolutional
analysis) and perfusion parameters (such as blood flow,
blood volume, mean transit time and time to peak) are
being used, implying a lack of standardisation. Therefore,
much more research is needed to define and validate its
role [62].
In conclusion, the RECIST Working Group believes
there is not sufficient validation or standardisation of FDG-
PET and other functional imaging modalities to substitute
for the anatomical assessment described in RECIST. It
would require a series of prospectively conducted multi-
centre clinical trials and a formal meta-analysis to validate
FDG-PET(/CT) as an appropriate end-point [28].
Conclusions
RECIST 1.1 has clarified many issues that had arisen after
publication of RECIST 1.0, e.g. reduction of the number of
target lesions, specifications on lymph nodes and new
lesions and detailed imaging specifications. At this
moment, the pool of data on molecular imaging and
volumetric tumour measurement is not sufficiently vali-
dated to incorporate into response assessment criteria and
therefore, unidimensional anatomical assessment of tu-
mour burden remains at this moment the best surrogate
endpoint. However, with all the emerging data, it is to be
expected that functional imaging methods will be incorpo-
rated in the next RECIST update.
Acknowledgements The authors would like to thank Gerrit Kracht
for helping to prepare the illustrations.
References
1. World Health Organization (1979)
WHO Handbook for reporting results
of cancer treatment. WHO Publication
No. 48, Geneva
2. Miller AB, Hoogstraten B, Staquet M,
Winkler A (1981) Reporting results of
cancer treatment. Cancer 47:207–214
3. Therasse P, Arbuck SG, Eisenhauer
EA, Wanders J, Kaplan RS, Rubinstein
L, Verweij J, Van Glabbeke M, Van
Oosterom AT, Christian MC, Gwyther
SG (2000) New guidelines to evaluate
the response to treatment in solid
tumors. J Natl Cancer Inst 92:205–216
4. Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, SargentD, Ford R,Dancey
J, Arbuck S, Gwyther S, Mooney M,
Rubinstein L, Shankar L, Dodd L,
Kaplan R, Lacombe D, Verweij J (2009)
New response evaluation criteria in solid
tumours: revised RECIST guideline
(version 1.1). Eur J Cancer 45:228–247.
doi:10.1016/j.ejca.2008.10.026
1464
5. Cheson BD, Pfistner B, Juweid ME,
Gascoyne RD, Specht L, Horning SJ,
Coiffier B, Fisher RI, Hagenbeek A,
Zucca E, Rosen ST, Stroobants S,
Lister TA, Hoppe RT, Dreyling M,
Tobinai K, Vose JM, Connors JM,
Federico M, Diehl V (2007) Revised
response criteria for malignant lym-
phoma. J Clin Oncol 25:579–586.
doi:10.1200/JCO.2006.09.2403
6. Bogaerts J, Ford R, Sargent D,
Schwartz LH, Rubinstein L, Lacombe
D, Eisenhauer E, Verweij J, Therasse P
(2009) Individual patient data analysis
to assess modifications of the RECIST
criteria. Eur J Cancer 45:248–260.
doi:10.1016/j.ejca.2008.10.027
7. Moskowitz CS, Jia X, Schwartz LH,
Gönen M (2009) A simulation study to
evaluate the impact of the number of
lesions measured on response assess-
ment. Eur J Cancer 45:300–310.
doi:10.1016/j.ejca.2008.11.010
8. Schwartz LH, Mazumdar M, Brown W,
Smith A, Panicek DM (2003) Variabil-
ity in response assessment in solid
tumors: effect of number of lesions
chosen for measurement. Clin Cancer
Res 9:4318–4323
9. Watanabe H, Kunitoh H, Yamamoto S,
Kawasaki S, Inoue A, Hotta K, Shiomi
K, Kusumoto M, Sugimura K, Saijo N
(2006) Effect of the introduction of
minimum lesion size on interobserver
reproducibility using RECIST guide-
lines in non-small cell lung cancer
patients. Cancer Sci 97:214–218
10. van Klaveren RJ, Aerts JGJV, de Bruin
H, Giaccone G, Manegold C, van
Meerbeeck JP (2004) Inadequacy of the
RECIST criteria for response evaluation
in patients with malignant pleural me-
sothelioma. Lung Cancer 43:63–69.
doi:10.1016/S0169-5002(3)00292-7
11. Byrne MJ, Nowak AK (2004) Modified
RECIST criteria for assessment of
response in malignant pleural meso-
thelioma. Ann Oncol 15:257–260.
doi:10.1093/annonc/mdh059
12. Plathow Ch, Klopp M, Thieke Ch,
Herth F, Thomas A, Schmaehl A, Zuna
I, Kauczor H-U (2008) Therapy re-
sponse in malignant pleural mesotheli-
oma - role of MRI using RECIST,
modified RECIST and volumetric ap-
proaches in comparison with CT. Eur
Radiol 18:1635–1643. doi:10.1007/
s00330-008-0918-9
13. James K, Eisenhauer E, Christian M,
Terenziani M, Vena D, Muldal A,
Therasse P (1999) Measuring response
in solid tumors: unidimensional versus
bidimensional measurement. J Natl
Cancer Inst 91:523–528
14. Trillet-Lenoir V, Freyer G, Kaemmerlen
P, Fond A, Pellet O, Lombard-Bohas C,
Gaudin JL, Lledo G, Mackiewicz R,
Gouttebel MC, Moindrot H, Boyer JD,
Chassignol L, Stremsdoerfer N,
Desseigne F, Moreau JM, Hedelius F,
Moraillon A, Chapuis F, Bleuse JP,
Barbier Y, Heilmann MO, Valette PJ
(2002) Assessment of tumour response
to chemotherapy for metastatic colo-
rectal cancer: accuracy of the RECIST
criteria. Br J Radiol 75:903–908
15. Cortes J, Rodriguez J,Diaz-Gonzalez JA,
Garzon C, Gurpide A, Arbea L, Gil-Bazo
I, Navarro V, Cambeiro M, Nicolas AI,
Martin-Algarra S, Garcia-Foncillas J,
Calvo E (2002) Comparison of unidi-
mensional and bidimensional measure-
ments in metastatic non-small cell lung
cancer. Br J Cancer 87:158–160.
doi:10.1038/sj.bjc.6600449
16. Prasad SR, Saini S, Sumner JE, Hahn PF,
Sahani D, Boland GW (2003) Radio-
logical measurement of breast cancer
metastases to lung and liver: comparison
between WHO (bidimensional) and RE-
CIST (unidimensional) guidelines. J
Comp Ass Tom 27:380–384
17. Mazumdar M, Smith A, Schwartz LH
(2004) A statistical simulation study
finds discordance between WHO criteria
and RECIST guideline. J Clin Epid
57:358–365. doi:10.1016/j.jclinepi.
2003.07.015
18. Schwartz LH, Colville JAC, Ginsberg
MS, Wang L, Mazumdar M, Kalaigian
J, Hricak H, Ilson D, Schwartz GK
(2006) Measuring tumor response and
shape change on CT: esophageal cancer
as a paradigm. Ann Oncol 17:1018–
1023. doi:10.1093/annonc/mdl058
19. Belton AL, Saini S, Liebermann K,
Boland GW, Halpern EF (2003) Tu-
mour size measurement in an oncology
clinical trial: comparison between off-
site and on-site measurements. Clin
Radiol 58:311–314. doi:10.1016/
S0009-9260(02)00577-9
20. Hopper KD, Kasales CJ, Van Slyke
MA, Schwartz TA, TenHave TR,
Jozefiak JA (1996) Analysis of inter-
observer and intraobserver variability
in CT tumor measurements. AJR Am J
Roentgenol 167:851–854
21. Erasmus JJ, Gladish GW, Broemeling
L, Sabloff BS, Truong MT, Herbst RS,
Munden RF (2003) Interobserver and
intraobserver variability in measure-
ment of non-small-cell carcinoma lung
lesions: implications for assessment of
tumor response. J Clin Oncol 21:2574–
2582. doi:10.1200/JCO.2003.01.144
22. Wormanns D, Kohl G, Klotz E,
Marheine A, Beyer F, Heindel W,
Diederich S (2004) Volumetric mea-
surements of pulmonary nodules at
multi-row detector CT: in vivo repro-
ducibility. Eur Radiol 14:86–92.
doi:10.1007/s00330-003-2132-0
23. Gietema HA, Schaefer-Prokop CM,
Mali WPTM, Groenewegen G, Prokop
M (2007) Pulmonary nodules: interscan
variability of semiautomated volume
measurements with multisection CT—
influence of inspiration level, nodule
size, and segmentation performance.
Radiology 245:888–894
24. Marten K, Auer F, Schmidt S, Kohl G,
Rummey EJ, Engelke C (2006) Inade-
quacy of manual measurements com-
pared to automated CT volumetry in
assessment of treatment response of
pulmonary metastases using RECIST
criteria. Eur Radiol 16:781–790.
doi:10.1007/s00330-005-0036-x
25. Keil S, Behrendt FF, Stanzel S, Sühling
M, Koch A, Bubenzer J, Mühlenbruch
G, Mahnken AH, Günther RW, Das M
(2008) Semi-automated measurement
of hyperdense, hypodense and hetero-
geneous hepatic metastasis on standard
MDCT slices. Comparison of semi-
automated and manual measurement of
RECIST and WHO criteria. Eur Radiol
18:2456–2465. doi:10.1007/s00330-
008-1050-6
26. Fabel M, von Tengg-Kobligk H, Giesel
FL, Bornemann L, Dicken V, Kopp-
Schneider A, Moser C, Delorme S,
Kauczor H-U (2008) Semi-automated
volumetric analysis of lymph nod me-
tastases in patients with malignant
melanoma stage III/IV—a feasibility
study. Eur Radiol 18:1114–1122.
doi:10.1007/s00330-008-0866-4
27. Ertl-Wagner BB, Blume JD, Peck D,
Udupa JK, Herman B, Levering A,
Schmalfuss IM (2009) Reliability of
tumor volume estimation from MR
images in patients with malignant gli-
oma. Results from the American Col-
lege of Radiology Imaging Network
(ACRIN) 6662 trial. Eur Radiol
19:599–609. doi:10.1007/s00330-008-
1191-7
28. Sargent DJ, Rubinstein L, Schwartz L,
Dancey JE, Gatsonis G, Dodd LE,
Shankar LK (2009) Validation of novel
imaging methodologies for use as can-
cer clinical trial end-points. Eur J
Cancer 45:290–299. doi:10.1016/j.
ejca.2008.10.030
29. McHugh K, Kao S (2003) Response
evaluation criteria in solid tumours
(RECIST): problems and need for
modifications in paediatric oncology?
Br J Radiol 76:433–436. doi:10.1259/
bjr/15521966
1465
30. Therasse P, Eisenhauer EA, Verweij J
(2006) RECIST revisited: a review of
validation studies on tumour assess-
ment. Eur J Cancer 42:1031–1039.
doi:10.1016/j.ejca.2006.01.026
31. Husband JE, Schwartz LH, Spencer J,
Ollivier L, King DM, Johnson R,
Reznik R (2004) Evaluation of the
response to treatment of solid tumours
—a consensus statement of the Inter-
national Cancer Imaging Society. Br J
Cancer 90:2256–2260
32. Glazer GM, Gross BH, Quint LE,
Francis IR, Bookstein FL, Orringer MB
(1985) Normal mediastinal lymph
nodes: number and size according to
American Thoracic Society Mapping.
AJR Am J Roentgenol 144:261–265
33. Matsuoka H, Masaki T, Sugiyama M,
Atomi Y, Ohkura Y, Sakamoto A
(2007) Morphological characteristics of
lateral pelvic lymph nodes in rectal
carcinoma. Langenbecks Arch Surg
392:543–547. doi:10.1007/s00423-
007-0181-6
34. Schwartz LH, Bogaerts J, Ford R,
Shankar L, Therasse P, Gwyther S,
Eisenhauer EA (2009) Evaluation of
lymph nodes with RECIST 1.1. Eur J
Cancer 45:261–267. doi:10.1016/j.
ejca.2008.10.028
35. Dorfman RE, Alpern MB, Gross BH,
Sandler MA (1991) Upper abdominal
lymph nodes: criteria for normal size
determined with CT. Radiology
180:310–322
36. McLoud TC, Bourgouin PM,
Greenberg RW, Kosiuk JP, Templeton
PA, Shepard JAO, Moore EH, Wain JC,
Mathisen DJ, Grillo HC (1992) Bron-
chogenic carcinoma: analysis of staging
in the mediastinum with CT by corre-
lative lymph node mapping and sam-
pling. Radiology 182:319–323
37. Tombal B, Rezazadeh A, Therasse P,
Van Cangh PJ, Vandeberg B, Lecouvet
FE (2005) Magnetic resonance imaging
of the axial skeleton enables objective
measurement of tumor response on
prostate cancer bone metastases. Pros-
tate 65:178–187. doi:10.1002/
pros.20280
38. Ratain MJ, Eisen T, Stadler WM,
Flaherty KT, Kaye SB, Rosner GL,
Gore M, Desai AA, Patnaik A, Xiong
HQ, Rowinksy E, Abbruzzese JL, Xia
C, Simantov R, Schwartz B, O’Dwyer
PJ (2006) Phase II placebo-controlled
randomized discontinuation trial of
Sorafenib in patients with metastatic
renal cell carcinoma. J Clin Oncol
24:2505–2512. doi:10.1200/
JCO.2005.03.6723
39. Pennell NA, Daniels GH, Haddad RI,
Ross DS, Evans T, Wirth LJ, Fidias PH,
Temel JS, Gurubhagavatula S, Suk
Heist R, Clark JR Lynch TJ (2008) A
phase II study of Gefitinib in patients
with advanced thyroid cancer. Thyroid
18:317–323. doi:10.1089/
thy.2007.0120
40. Shephard FA, Rodrigues Pereira J,
Ciuleanu T, Huat Tan E, Hirsch V,
Thongprasert S, Campos D,
Maoleekoonpiroj S, Smylie M, Martins
R, van Kooten M, Dediu M, Findlay B,
Tu D, Johnston D, Bezjak A, Clark G,
Santabárbara P, Seymour L, for the
National Cancer Institute of Canada
Clinical Trials Group (2005) Erlotinib
in previously treated non-small-cell
lung cancer. N Engl J Med 353:123–
132
41. Hudes G, Carducci M, Tomczak P,
Dutcher J, Figlin R, Kapoor A,
Staroslawska E, Sosman J, McDermott
D, Bodrogi I, Kovacevic Z, Lesovoy V,
Schmidt-Wolf IGH, Barbarash O,
Gokmen E, O’Toole T, Lustgarten S,
Moore L, Motzer RJ, for the Global
ARCC Trial (2007) Temsirolimus, in-
terferon alfa, or both for advanced
renal-cell carcinoma. N Engl J Med
356:2271–2281
42. Hurwitz H, Fehrenbacher L, Novotny
W, Cartwright T, Hainsworth J, Heim
W, Berlin J, Baron A, Griffing S,
Holmgren E, Ferrara N, Fyfe G, Rogers
B, Ross R, Kabbinavar F (2004)
Bevacizumab plus irinotecan, fluoro-
uracil, and leucovorin for metastatic
colorectal cancer. N Engl J Med
350:2335–2342
43. Llovet JM, Di Bisceglie AM, Bruix J,
Kramer BS, Lencioni R, Zhu AZ,
Sherman M, Schwartz M, Lotze M,
Talwalkar J, Gores GJ (2008) Design
and endpoints of clinical trials in
hepatocellular carcinoma. J Natl Cancer
Inst 100:698–711. doi:10.1093/jnci/
djn134
44. Choi H, Charnsangavej C, Faria SC,
Macapinlac HA, Burgess MA, Patel
SR, Chen LL, Podoloff DA, Benjamin
RS (2007) Correlation of computed
tomography and positron emission
tomography in patients with metastatic
gastrointestinal stromal tumor treated at
a single institution with Imatinib Me-
sylate: proposal of new computed
tomography response criteria. J Clin
Oncol 25:1753–1759. doi:10.1200/
JCO.2006.07.3049
45. Benjamin RS, Choi H, Macapinlac HA,
Burgess MA, Patel SR, Chen LL,
Podoloff DA Charnsangavej C (2007)
We should desist using RECIST, at
least in GIST. J Clin Oncol 25:1760–
1764. doi:10.1200/JCO.2006.07.3411
46. Kawamoto S, Permpongkosol S,
Bluemke DA, Fishman EK, Solomon
SB (2007) Sequential changes after
radiofrequency ablation and cryoabla-
tion of renal neoplasms: role of CT and
MR imaging. Radiographics 27:343–
355. doi:10.1148/rg.272065119
47. Kim Y-S, Rhim H, Lim HK (2009)
Imaging after radiofrequency ablation
of hepatic tumors. Semin Ultrasound
CT MRI 30:49–66. doi:10.1053/j.
sult.2008.12.004
48. Weber WA (2009) Assessing tumor
response to therapy. J Nucl Med 50:1S–
10S. doi:10.2967/jnumed.108.057174
49. Hutchings M, Barrington SF (2009)
PET/CT for therapy response assess-
ment in lymphoma. J Nucl Med
50:21S–30S. doi:10.2967/
jnumed.108.057190
50. Hicks RJ (2009) Role of F-FDG PET in
assessment of response in non-small
cell lung cancer. J Nucl Med 50:31S–
42S. doi:10.2967/jnumed.108.057216
51. de Geus-Oei L-F, Vriens D, van
Laarhoven HWM, van der Graaf WTA,
Oyen WJG (2009) Monitoring and
predicting response to therapy with 18F-
FDG PET in colorectal cancer: a sys-
tematic review. J Nucl Med 50:43S–
54S. doi:10.2967/jnumed.108.057224
52. Avril N, Sassen S, Roylance R (2009)
Response to therapy in breast cancer. J
Nucl Med 50:55S–63S. doi:10.2967/
JNUMED.108.057240
53. Boellaard R (2009) Standards for PET
image acquisition and quantitative data
analysis. J Nucl Med 50:11S–20S.
doi:10.2967/jnumed.108.057182
54. Wahl RL, Jacene H, Kasamon Y, Lodge
MA (2009) From RECIST to PER-
CIST: evolving considerations for PET
response criteria in solid tumors. J Nucl
Med 50:122S–150S. doi:10.2967/
jnumed.108.057307
55. Galbraith SM, Rustin GJS, Lodge MA,
Taylor J, Stirling JJ, Jameson M,
Thompson P, Hough D, Gumbrell L,
Padhani AR (2002) Effects of 5,6-
dimethylxanthenone-4-acetic acid on
human tumor microcirculation assessed
by dynamic contrast-enhanced mag-
netic resonance imaging. J Clin Oncol
20:3826–3840. doi:10.1200/
JCO.2002.09.144
56. van Rijswijk CSP, Geirnaerdt MJA,
Hogendoorn PCW, Peterse JL, van
Coevorden F, Taminiau AHM,
Tollenaar RAEM, Kroon BBR, Bloem
JL (2003) Dynamic contrast-enhanced
MR imaging in monitoring response to
isolated limb perfusion in high-grade




57. O’Connor JPB, Jackson A, Parker
GJM, Jayson GC (2007) DCE-MRI
biomarkers in the clinical evaluation of
antiangiogenic and vascular disrupting
agents. Br J Cancer 96:189–195.
doi:10.1038/sj.bjc.6603515
58. Yankeelov TE, Lepage M, Chakravarthy
A, Broome EE, Niermann KJ, Kelley
MC,Meszoely I, Mayer IA, Herman CR,
McManns K, Price RR, Gore JC (2007)
Integration of quantitativeDCE-MRI and
ADC mapping to monitor treatment
response in human breast cancer: initial
results. Magn Res Imag 25:1–13.
doi:10.1016/j.mri.2006.09.006
59. Padhani AR, Liu G, Mu-Koh D,
Chenevert TL, Thoeny HC, Takahara T,
Dzik-Jurasz A, Ross BD, Van Cauteren
M, Collins D, Hammond DA,
Rustin GJS, Taouli B, Choyke PL
(2009) Diffusion-weighted magnetic
resonance imaging as a cancer biomar-
ker: consensus and recommendations.
Neoplasia 11:102–125. doi:10.1593/
neo.81328
60. Kan Z, Phongkitkarun S, Kobayashi S,
Tang Y, Ellis LM, Lee TY,
Charnsangavej C (2005) Functional CT
for quantifying tumor perfusion in
antiangiogenic therapy in a rat model.
Radiology 237:151–158. doi:10.1148/
radiol.2363041293
61. Meijerink MR, van Cruijsen H,
Hoekman K, Kater M, van Schaik C,
van Waesberghe JHTM, Giaccone G,
Manuliu RA (2007) The use of perfu-
sion CT for the evaluation of therapy
combining AZD2171 with gefitinib in
cancer patients. Eur Radiol 17:1700–
1713. doi:10.1007/s00330-006-0425-9
62. Kambadakone AR, Sahani DV (2009)
Body perfusion CT: technique, clinical
applications and advances. Radiol Clin
N Am 47:161–178. doi:10.1016/j.
rcl.2008.11.003
1467
